Ermia Mousavi Mohammadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ermia Mousavi Mohammadi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Mohsen Rajati
Sinus and Surgical Endoscopic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications Hossein Zarrinfar
Mashhad University of Medical Sciences
1 shared publication- Hossein Zarrinfar
Allergy research Center, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication - Imaneh Roshanzamir
Department of Otolaryngology ‐ Head & Neck Surgery Mashhad University of Medical Sciences Mashhad Iran
1 shared publication - Mohammad Reza Majidi
Department of Otolaryngology ‐ Head & Neck Surgery Mashhad University of Medical Sciences Mashhad Iran
1 shared publication
Latest Publications
- 3 November 2026
- Published by Wiley in The Laryngoscope
Effect of Topical Tranexamic Acid in Acute Spontaneous Epistaxis: A Randomized Controlled Trial
Objective: Persistent epistaxis and early rebleeding remain clinical challenges despite the self‐limiting nature of many cases. Identification of a simple, noninvasive strategy for hemostasis and recurrence prevention remains a clinical priority. Topical tranexamic acid (TXA) is a potential hemostatic agent, but evidence regarding its effectiveness, particularly for rebleeding, is limited and inconsistent. This study evaluated the role of topical TXA in controlling bleeding and preventing rebleeding in acute spontaneous epistaxis. Methods: In this randomized, double‐blind, placebo‐controlled trial, patients presenting with acute spontaneous epistaxis unresponsive to initial first‐aid measures were enrolled and randomly assigned to receive topical tranexamic acid (TXA) or placebo. Results: A total of 162 patients were included in the study, including 76 in the TXA group and 86 in the control group. Topical TXA was significantly more effective than placebo in achieving initial hemostasis in the emergency department setting ( p = 0.047). No significant differences were observed in rebleeding within 24 h (risk ratio 0.45 (95% CI, 0.17–1.24; p = 0.119)), or in significant rebleeding within 24 h (risk ratio: 1.50 (95% CI, 0.26–8.70; p = 0.651)). Conclusion: In spontaneous epistaxis, the direct application of topical tranexamic acid to the bleeding site is a useful adjunct for achieving hemostasis. This targeted approach may allow effective bleeding control with a smaller amount of the drug, potentially reducing the risk of adverse effects associated with higher doses. Level of Evidence: 1
- 3 November 2026
- Published by Wiley in The Laryngoscope
Effect of Topical Tranexamic Acid in Acute Spontaneous Epistaxis: A Randomized Controlled Trial
Objective: Persistent epistaxis and early rebleeding remain clinical challenges despite the self‐limiting nature of many cases. Identification of a simple, noninvasive strategy for hemostasis and recurrence prevention remains a clinical priority. Topical tranexamic acid (TXA) is a potential hemostatic agent, but evidence regarding its effectiveness, particularly for rebleeding, is limited and inconsistent. This study evaluated the role of topical TXA in controlling bleeding and preventing rebleeding in acute spontaneous epistaxis. Methods: In this randomized, double‐blind, placebo‐controlled trial, patients presenting with acute spontaneous epistaxis unresponsive to initial first‐aid measures were enrolled and randomly assigned to receive topical tranexamic acid (TXA) or placebo. Results: A total of 162 patients were included in the study, including 76 in the TXA group and 86 in the control group. Topical TXA was significantly more effective than placebo in achieving initial hemostasis in the emergency department setting ( p = 0.047). No significant differences were observed in rebleeding within 24 h (risk ratio 0.45 (95% CI, 0.17–1.24; p = 0.119)), or in significant rebleeding within 24 h (risk ratio: 1.50 (95% CI, 0.26–8.70; p = 0.651)). Conclusion: In spontaneous epistaxis, the direct application of topical tranexamic acid to the bleeding site is a useful adjunct for achieving hemostasis. This targeted approach may allow effective bleeding control with a smaller amount of the drug, potentially reducing the risk of adverse effects associated with higher doses. Level of Evidence: 1
- Open Access
- 20 January 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (1) , e70101
Unusual Presentation of a Rare Disease: A Case Report of Fungal Necrotizing Otitis Media and Mastoiditis
Acute necrotizing otitis media is a severe middle ear infection which causes necrosis of the tympanic cavity. A 54‐year‐old female was presented who suffered from diabetes mellitus and end‐stage renal disease presenting with severe otalgia, initially thought to be necrotizing otitis externa. She rapidly progressed to total necrosis of the tympanic membrane. Further assessments confirmed a fungal disease caused by Candida tropicalis and Aspergillus flavus. Immediate antifungal therapy with amphotericin B and subsequent radical mastoidectomy managed to control the disease with no sign of necrosis after 3 months. Early diagnosis, aggressive systemic antifungal treatment, and surgical debridement are vital components for successful management of such cases.
- 20 January 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (1) , e70101
Open AccessUnusual Presentation of a Rare Disease: A Case Report of Fungal Necrotizing Otitis Media and Mastoiditis
Acute necrotizing otitis media is a severe middle ear infection which causes necrosis of the tympanic cavity. A 54‐year‐old female was presented who suffered from diabetes mellitus and end‐stage renal disease presenting with severe otalgia, initially thought to be necrotizing otitis externa. She rapidly progressed to total necrosis of the tympanic membrane. Further assessments confirmed a fungal disease caused by Candida tropicalis and Aspergillus flavus. Immediate antifungal therapy with amphotericin B and subsequent radical mastoidectomy managed to control the disease with no sign of necrosis after 3 months. Early diagnosis, aggressive systemic antifungal treatment, and surgical debridement are vital components for successful management of such cases.
- Open Access
- 28 July 2024
- Published by Wiley
Unusual Presentation of a Rare Disease: A Case Report of Fungal Necrotizing Otitis Media and Mastoiditis
Acute necrotizing otitis media (ANOM) is a severe middle ear infection which causes necrosis of the tympanic cavity. A 54-year-old female was presented who suffered from diabetes mellitus and end-stage renal disease presenting with severe otalgia, initially thought to be necrotizing otitis externa (NOE). She rapidly progressed to total necrosis of
- 28 July 2024
- Published by Wiley
Open AccessUnusual Presentation of a Rare Disease: A Case Report of Fungal Necrotizing Otitis Media and Mastoiditis
Acute necrotizing otitis media (ANOM) is a severe middle ear infection which causes necrosis of the tympanic cavity. A 54-year-old female was presented who suffered from diabetes mellitus and end-stage renal disease presenting with severe otalgia, initially thought to be necrotizing otitis externa (NOE). She rapidly progressed to total necrosis of